The International Cancer conference 2014 program has been developed around a fundamental concept that, Cancer is not a single disease, Specific biological processes and distinct gene pathways are associated with prognosis of the disease and its sensitivity to chemotherapy, radiotherapy and targeted agents in different subtypes of cancers. A primary challenge for future treatment of patients with cancer will be to distinguish genes and pathways that "drive鈥� cancer proliferation from genes and pathways that have no primary role in the development of cancer. The identification of functional pathways that are enriched for mutated genes will select sub-population of patients that will most likely be sensitive to chemotherapy or to biology driven targeted agents, this might help us personalize treatment according to specific subtypes of cancer, in order to maximize efficacy while minimizing the extent of treatment. The detailed understanding of the above said biological process will open new gates for cancer prevention, diagnosis, and treatment regimes.
One of the most important factors in the survival of cancer patients is detection at an early stage. Clinical assays that detect the early events of cancer offer an opportunity to intervene and prevent cancer progression. Biomarkers are important molecular signatures of the phenotype of a cell that aid in early cancer detection and risk assessment. Although new information and technologies are clearly important for new biomarker discovery, we face major hurdles in translating new findings into clinical application. During this Cancer conference, we discuss examples of recent advances and limitations in cancer biomarker identification and validation, and the implications for cancer prevention.
These continued advancements in cancer therapies are allowing us to tailor the treatment to each individual patient in order to achieve cost effective, best results, fewer side effects and overall better outcomes. This conference will address this very important aspect and pave a platform to amalgamate the basic research and translational sciences.
One of the most important factors in the survival of cancer patients is detection at an early stage. Clinical assays that detect the early events of cancer offer an opportunity to intervene and prevent cancer progression. Biomarkers are important molecular signatures of the phenotype of a cell that aid in early cancer detection and risk assessment. Although new information and technologies are clearly important for new biomarker discovery, we face major hurdles in translating new findings into clinical application. During this Cancer conference, we discuss examples of recent advances and limitations in cancer biomarker identification and validation, and the implications for cancer prevention.
These continued advancements in cancer therapies are allowing us to tailor the treatment to each individual patient in order to achieve cost effective, best results, fewer side effects and overall better outcomes. This conference will address this very important aspect and pave a platform to amalgamate the basic research and translational sciences.
